Argenx profit surges 116% as VYVGART sales hit $1.3B in record Q1
Argenx (NASDAQ:ARGX) delivered a powerful start to 2026, reporting first-quarter financial results that demonstrate the accelerating commercial scale of its flagship FcRn blocker, VYVGART.






_1395288_640x360_2499099203704-640x360.webp&w=3840&q=75)
_1395285_640x360_2499099203708-640x360.webp&w=3840&q=75)



_1395242_640x360_2499078723812-640x360.webp&w=3840&q=75)